CellCentric, a clinical-stage biotechnology firm, has successfully closed an oversubscribed Series D financing round, securing $220 million. The funding was spearheaded by Venrock Healthcare Capital Partners and will be instrumental in advancing the company's lead candidate, inobrodib. This capital infusion is designated to support pivotal trials for the first-in-class oral p300/CBP inhibitor aimed at treating multiple myeloma.
Advancing Late-Stage Clinical Development
The proceeds from this financing are earmarked for the progression of inobrodib through crucial clinical studies. This includes the continued enrollment in the Phase 2 DOMMINO-1 study and the planned initiation of the global Phase 3 DOMMINO-2 trial later this year. The funding will also facilitate the expansion of inobrodib's application into additional combination and maintenance treatment scenarios for cancer patients.
A Novel Oral Therapy for a Critical Need
Inobrodib represents a new therapeutic modality for patients with multiple myeloma, particularly those who have exhausted other treatment options. As an orally administered capsule, it offers a convenient at-home treatment option without the need for intensive hospital monitoring. This first-in-class inhibitor targets p300/CBP, presenting a fresh approach for a patient population with a significant and growing unmet need.
Strong Clinical Efficacy and Investor Confidence
Recent clinical data has bolstered confidence in inobrodib's potential as a transformative treatment. Phase 2 results demonstrated that the drug, when combined with pomalidomide and dexamethasone, achieved deep responses in heavily pretreated patients. This combination, known as InoPd, showed at least a two-fold increase in response rates compared to historical alternative therapies for this patient group.
The consistency of clinical activity alongside a manageable safety profile has attracted significant investor interest. Ken Greenberg of Venrock highlighted the drug's potential to play an important role in the multiple myeloma treatment landscape. This strong syndicate of new and existing investors underscores the belief in inobrodib's novel, additive approach to cancer therapy.
Expanding Therapeutic Horizons
The development program for inobrodib is extensive, with the drug having been evaluated in over 500 patients to date. Clinical activity has been observed not only in hematologic malignancies but also in solid tumors, suggesting a broader potential. The U.S. Food and Drug Administration has already granted both Fast Track and orphan drug designations to inobrodib for relapsed or refractory multiple myeloma.
CellCentric is actively exploring inobrodib's utility in combination with other advanced treatments, including bispecific therapies like elranatamab and teclistamab. The company is also investigating its proof of concept in a maintenance setting to prevent disease recurrence. CellCentric retains full development and commercial rights, allowing it to freely expand the program with other therapeutic agents.
Strategic Vision for a New Treatment
Company leadership expressed enthusiasm for the support from top-tier investors, which validates the drug's potential. CEO Will West emphasized that inobrodib could become a vital new option for patients, especially following treatment with bispecific T cell engagers. This financing positions the transatlantic company to complete its registration-enabling studies and advance toward commercialization.
This substantial $220 million financing marks a pivotal moment for CellCentric and its lead candidate, inobrodib. The capital provides a clear runway to complete late-stage trials and potentially deliver a new, convenient oral therapy for multiple myeloma patients. The strong backing from the investment community signals significant confidence in the drug's ability to address a critical unmet need in oncology.